Blog

April 5-10, San Diego Pepper Bio is on a mission to decipher the root causes of diseases and identify effective treatments—thereby illuminating the fastest, safest path to drug discovery. COMPASS, our ML-driven platform, is built on the world's first and largest proprietary transomics database, integrating genomic, transcriptomic, proteomic, and phosphoproteomic data. Our approach offers a comprehensive understanding of biological systems based not just on expression but also on the activity…

Tell us a bit about your background. First, I have to start by saying how appreciative I am because I’ve always had exceptional people supporting me and advising me in my career path. I would say that what I am doing now is an amalgam of all the pieces of the mosaic of my life journey which has been dedicated to improving the healthcare system and advancing the development of…

Pepper Bio is on a mission to put an end to untreatable diseases by enabling more effective drug discovery through the use of transomic analysis. We do this using our COMPASS platform that integrates data across the genomic, transcriptomic, proteomic, and phosphoproteomic biological layers to uncover global, functional and causal understanding of complex biological processes. At the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference, hosted by the American Association…

As a scientist focused on tangible data and results, it’s easy to be sceptical about the impact of legislative acts: the path from Congress to the lab is long and winding. Despite the subtle change and lack of immediate impact on patients, the FDA Modernization Act 2.0 is anything but inconsequential. I think, in truth, that it may be the spark needed to ignite the next era of animal-free drug…

Everyone knows someone with cancer, so this question may be confusing, but: Does anyone have cancer anymore? What I mean is: At first, there was cancer. Now, there is chronic myeloid leukemia and acute lymphocytic leukemia; primary colorectal lymphomas and gastrointestinal stromal tumors; and six subgroups of triple-negative breast cancer. We’ve outgrown the blanket term “cancer,” and it’s making a positive difference in how we treat and overcome disease. In…